Abstract
Hematopoietic stem cell transplant (HSCT) patients face an array of proximate and remote cardiovascular events, including congestive heart failure (CHF), coronary vascular disease (CAD), pericardial disease, and arrhythmias. Toxicities may be classified temporally, appearing in acute (<2 weeks), early (2 weeks–3 months), or late (>3 months) periods following HSCT. These patients appear to be at increased risk for both subclinical and overt cardiovascular toxicities. Studies have been inconsistent in estimating the amount of clinically relevant risk, with reports ranging from no increased risk to greater than 40%. Variability in the incidence of cardiac events reported in the literature results from small patient populations, lack of matched controls, indirect measures of cardiac dysfunction, and improvements in cardiac disease management over time.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Akahori, M., Nakamae, H., Hino, M., et al. (2003). Electrocardiogram is very useful for predicting acute heart failure following myeloablative chemotherapy with hematopoietic stem cell transplantation rescue. Bone Marrow Transplant, 31:585–590.
Armenian, S.H., Sun, C.L., Francisco, L., et al. (2008). Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol, 26:5537–5543.
Baker, K.S., Ness, K.K., Steinberger, J., et al. (2007). Diabetes, hypertension and cardiovascular events in survivors of hematopoietic cell transplantation: A report from the bone marrow transplant survivor study. Blood, 109:1765–1772.
Bearman, S.I., Petersen, F.B., Schor, R.A., et al. (1990). Radionuclide ejection fractions in evaluation of patients being considered for bone marrow transplantation. Bone Marrow Transplant, 5:173–177.
Cazin, B., Gorin, N.C., Laporte, J.P., et al. (1986). Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer, 57:2061–2069.
Ciresi, D.L., Lloyd, M.A., Sandberg, S.M., et al. (1992). The sodium retaining effects of cyclosporine. Kidney Int, 41:1599–1605.
Goldberg, M.A., Antin, J.H., Guinan, E.C., et al. (1986). Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor. Blood, 68:1114–1118.
Hertenstein, B., Stefanic, M., Scholz, M., et al. (1994). Cardiac toxicity of BMT: Predictive value of cardiologic evaluation before transplant. J Clin Oncol, 12:998–1004.
Hildago, J.D., Krone, R., Rich, M.W., et al. (2004). Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: Incidence, risk factors, and outcomes. Bone Marrow Transplant, 34:615–619.
Morandi, P., Ruffini, P.A., Benvenuto, G.M., et al. (2005). Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant, 35:323–334.
Murdych, T., Weisdorf, D.J. (2001). Serious cardiac complications during bone marrow transplantation at the University of Minnesota. 1977–1997. Bone Marrow Transplant, 28:283–287.
Nakamae, H., Tsumura, K., Hino, M., et al. (2000). QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Lancet, 355:805–806.
Rhodes, M., Lautz, T., Kavanaugh-McHugh, A., et al. (2005). Pericardial effusion and cardiac tamponade in pediatric stem cell transplant recipients. Bone Marrow Transplant, 36:139–144.
Sakata-Yanagimoto, M., Kanda, Y., Nakagawa, M., et al. (2004). Predictors for severe cardiac complications after hematopoietic stem cell transplantation. Bone Marrow Transplant, 33:1043–1047.
Santos, G.W., Senbrenner, L.L., Bruke, P.J. et al. (1972). The use of cyclophosphamide for clinical marrow transplantation. Transplant Proc, 4:559–564.
Tichelli, A., Bucher, C, Rovo, A., et al. (2007). Premature cardiovascular disease after allogeneic hematopoietic stem cell transplant. Blood, 110:3463–3471.
Tang, W.H.W., Thomas, S., Kalaycio, M., et al. (2004). Clinical outcomes of patients with impaired left ventricular ejection fraction undergoing autologous bone marrow transplantation: Can we safely transplant patients with impaired ejection fraction? Bone Marrow Transplant, 34:603–607.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Greenman, C. (2010). Cardiovascular Complications. In: Maziarz, R., Slater, S. (eds) Blood and Marrow Transplant Handbook. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7506-5_20
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7506-5_20
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-7505-8
Online ISBN: 978-1-4419-7506-5
eBook Packages: MedicineMedicine (R0)